So far several clinical trials conducted in NSCLC patients with HER2 aberration showed a modest efficacy of small molecule TKIs (e.g. afatinib, dacomitinib), anti-HER2 antibodies administered alone (e.g. trastuzumab) or in association with chemotherapy (e.g. trastuzumab+carboplatin/paclitaxel) or antibody-drug coniugate (ADC) (e.g.T-DM1) (41). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.